Impel Pharmaceuticals rises on smaller-than-expected Q4 loss

IPI Legacy Liquidation Co

24/03/2023 13:20

** Shares of Impel Pharmaceuticals Inc.  IMPL.O  up 14.50%
at $1.50 premarket
    ** Co reports Q4 loss of $0.97/shr, smaller than analysts'
expectations of $1.12/shr
    ** Says co has sufficient capital to fund ops into Q3 2023
    ** Also, sees total prescriptions within the range of
80,000–110,000 for Trudhesa for 2023; Trudhesa is a nasal spray
used for treating active migraine
    ** 3 of 4 brokerages rate the stock "buy" or higher, and 1
"hold" ; their median PT is $10.50
    ** IMPL fell 56.55% in 2022 

 (Reporting By Akshita Toshniwal)
 ((Akshita.Toshniwal@thomsonreuters.com))